前列腺特异性抗原密度联合磁共振成像在前列腺穿刺决策中的多机构回顾性研究
基于国际多中心PROMOD数据库2512例在穿刺前接受PSAd和前列腺MRI的男性回顾性分析,比较10种基于PSAd和MRI评分策略的穿刺避免率与漏诊率,决策曲线分析显示活检初治患者最佳策略为#7,避免41.2%穿刺但漏诊10.9% csPCa;临床低漏诊策略#10和#5分别避免27%和14.7%穿刺,漏诊4%和1.7% csPCa。
要点
- PSAd联合MRI可个体化决策前列腺穿刺,权衡避免穿刺与漏诊csPCa风险。
- 活检初治患者DCA最佳策略#7避免41.2%穿刺,漏诊10.9% csPCa。
- 低漏诊策略#10避免27%穿刺漏诊4% csPCa,#5避免14.7%穿刺漏诊1.7% csPCa。
核心结论
- 联合PSAd与MRI发现可基于患者和临床医生可接受的漏诊风险个体化决定是否行前列腺穿刺。
研究设计与样本
- 回顾性分析国际多中心PROMOD数据库,纳入2013至2019年间2512例在穿刺前接受PSAd和前列腺MRI的男性。
主要发现
- 活检初治患者DCA最佳策略#7避免41.2%穿刺,漏诊44% GGG 1和10.9% csPCa。
- 策略#10避免27%穿刺,漏诊24.4% GGG 1和4% csPCa。
- 策略#5避免14.7%穿刺,漏诊9.3% GGG 1和1.7% csPCa。
- 既往阴性活检患者结果相似。
关键数值与推荐
- 策略#7:PI-RADS/Likert 4-5或PI-RADS/Likert 3且PSAd>0.2。
- 策略#10:PI-RADS/Likert 4-5或PI-RADS 3且PSAd>0.10或PSAd>0.2。
- 策略#5:PI-RADS/Likert 3-5或PSAd>0.15。
- 参考标准为联合系统与靶向穿刺。
临床怎么用
- 可根据中心可用工具和患者可接受的漏诊风险选择PSAd联合MRI策略来减少不必要穿刺。
- 与患者沟通个体化csPCa漏诊风险以共同决策。
局限性
- 回顾性研究设计。
- MRI和病理结果无中心化复核。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies suggested that prostate-specific antigen (PSA) density (PSAd) combined with magnetic resonance imaging (MRI) may help avoid unnecessary prostate biopsy (PB) with a limited risk of missing clinically significant prostate cancer (csPCa; Gleason grade group [GGG] >1). OBJECTIVE: To define optimal diagnostic strategies based on the combined use of PSAd and MRI in patients at risk of prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of the international multicenter Prostate MRI Outcome Database (PROMOD), including 2512 men having undergone PSAd and prostate MRI before PB between 2013 and 2019, was performed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Rates of avoided PB, missed GGG 1, and csPCa according to 10 strategies based on PSAd values and MRI reporting scores (Prostate Imaging Reporting and Data System [PI-RADS]/Likert/IMPROD biparametric prostate MRI Likert). Decision curve analysis (DCA) was used to statistically compare the net benefit of each strategy. Combined systematic and targeted biopsies were used for reference. RESULTS AND LIMITATIONS: According to DCA, the best strategy in biopsy-naive patients was #7 (PI-RADS/Likert 4-5 or PI-RADS/Likert 3 if PSAd >0.2), which avoided 41.2% PBs while missed 44% of GGG 1 and 10.9% of csPCa cases. From a clinical standpoint, however, strategies with a lower risk of missing csPCa included #10 (PI-RADS/Likert 4-5 or PI-RADS 3 if PSAd >0.10 or PSAd >0.2), which avoided 27% PBs while missing 24.4% GGG 1 and 4% csPCa cases, or #5 (PI-RADS/Likert 3-5 or PSAd>0.15), which avoided 14.7% PBs while missing 9.3% GGG 1 and 1.7% csPCa cases. Similar results were found in patients with a previous negative biopsy. This study is limited by its retrospective nature, and no central review of MRI and histopathological findings. CONCLUSIONS: Combined PSAd and MRI findings allows individualization of the decision to perform PB on the basis of the risk of missing PCa that both patients and clinicians are ready to accept to avoid this procedure. PATIENT SUMMARY: We compared several biopsy strategies based on a combination of prostate magnetic resonance imaging findings and prostate-specific antigen density, providing a readily available tool for each center and practicing urologist to counsel patients about their individual risk of significant prostate cancer.
引用
- Falagario UG, Jambor I, Lantz A, et al. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). Eur Urol Oncol. 2020. PMID: 32972896. doi:10.1016/j.euo.2020.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。